Literature DB >> 28511433

Clinico-Radiologic and Spirometric Profile of an Indian Population with Post-Tuberculous Obstructive Airway Disease.

Avradip Santra1, Pravati Dutta2, Rekha Manjhi3, Sudarsan Pothal4.   

Abstract

INTRODUCTION: Tuberculosis is a public health problem in developing countries and in spite of receiving adequate anti-tuberculous therapy, patients often continues to have several post-tuberculous sequelae, especially airflow limitation. AIM: To evaluate pulmonary function by spirometry among post-tuberculosis cases with airway obstruction and their relationship with smoking.
MATERIALS AND METHODS: All patients who presented to the pulmonary medicine Outpatient Department (OPD) with symptoms of obstructive airway disease and had completed adequate anti-tuberculous therapy for pulmonary tuberculosis were taken up for study. They were initially evaluated with sputum smear for Acid Fast Bacilli (AFB) and chest X-ray. Patients without evidence of active tuberculosis underwent spirometry and those having post-bronchodilator Forced Expiratory Volume in first second (FEV1)/ Forced Vital Capacity (FVC) FEV1/FVC<0.7 were taken up for final analysis. Spirometric parameters were compared between smokers and non-smokers.
RESULTS: Out of 138 finally selected cases, 84.06% were male and 71.01% were within age range of 40-69 years. Significant positive association was found between extent of radiologic lesion and severity of airflow obstruction. Purely obstructive pattern was found in 27.54% cases and 72.46% showed mixed pattern. Patients with mixed ventilatory abnormality had worse pulmonary function and poorer bronchodilator reversibility than patients with pure obstruction. Comparison of post-bronchodilator FEV1, FVC, Peak Expiratory Flow (PEF) and Forced Expiratory Flow (FEF) 25-75 between smokers and non-smokers did not show statistically significant difference.
CONCLUSION: Majority of patients with post-tuberculous obstructive airway disease have associated restrictive component. But smoking did not cause significant alteration in pulmonary function among such patients.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Forced expiratory flow; Peak expiratory flow

Year:  2017        PMID: 28511433      PMCID: PMC5427359          DOI: 10.7860/JCDR/2017/24555.9529

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  20 in total

1.  Determinants of spirometric abnormalities among silicotic patients in Hong Kong.

Authors:  Chi C Leung; Kwok C Chang; Wing S Law; Wing W Yew; Cheuk M Tam; Chi K Chan; Man Y Wong
Journal:  Occup Med (Lond)       Date:  2005-09       Impact factor: 1.611

Review 2.  Smoking and tuberculosis: the epidemiological association and immunopathogenesis.

Authors:  P D O Davies; W W Yew; D Ganguly; A L Davidow; L B Reichman; K Dheda; G A Rook
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-12-01       Impact factor: 2.184

3.  Functional profile of patients with tuberculosis sequelae in a university hospital.

Authors:  Lucia Maria Macedo Ramos; Nara Sulmonett; Cid Sergio Ferreira; Juliana Fulgêncio Henriques; Silvana Spíndola de Miranda
Journal:  J Bras Pneumol       Date:  2006 Jan-Feb       Impact factor: 2.624

4.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.

Authors:  Alan D Lopez; Colin D Mathers; Majid Ezzati; Dean T Jamison; Christopher J L Murray
Journal:  Lancet       Date:  2006-05-27       Impact factor: 79.321

5.  [Functional evaluation in patients with pulmonary tuberculosis sequelae].

Authors:  F C Di Naso; J S Pereira; S J Schuh; G Unis
Journal:  Rev Port Pneumol       Date:  2011-07-30

6.  Pulmonary impairment after tuberculosis.

Authors:  Jotam G Pasipanodya; Thaddeus L Miller; Mauricio Vecino; Guadalupe Munguia; Robert Garmon; Sejong Bae; Gerry Drewyer; Stephen E Weis
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

7.  Post treatment sequelae of multi-drug resistant tuberculosis patients.

Authors:  Neeta Singla; Rupak Singla; Sheron Fernandes; Digamber Behera
Journal:  Indian J Tuberc       Date:  2009-10

8.  Wheeze, asthma diagnosis and medication use: a national adult survey in a developing country.

Authors:  R I Ehrlich; N White; R Norman; R Laubscher; K Steyn; C Lombard; D Bradshaw
Journal:  Thorax       Date:  2005-11       Impact factor: 9.139

9.  Chronic obstructive airways disease following treated pulmonary tuberculosis.

Authors:  P A Willcox; A D Ferguson
Journal:  Respir Med       Date:  1989-05       Impact factor: 3.415

10.  Clinical presentation and predictors of outcome in patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring admission to intensive care unit.

Authors:  Alladi Mohan; Raya Premanand; Lebaka Narayana Reddy; Mangu H Rao; Surendra K Sharma; Ranjit Kamity; Srinivas Bollineni
Journal:  BMC Pulm Med       Date:  2006-12-19       Impact factor: 3.317

View more
  4 in total

1.  Difference in systemic inflammation and predictors of acute exacerbation between smoking-associated COPD and tuberculosis-associated COPD.

Authors:  Jee Youn Oh; Young Seok Lee; Kyung Hoon Min; Gyu Young Hur; Sung Yong Lee; Kyung Ho Kang; Chin Kook Rhee; Seoung Ju Park; Jae Jeong Shim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-18

2.  Tuberculosis related disability: a systematic review and meta-analysis.

Authors:  Kefyalew Addis Alene; Kinley Wangdi; Samantha Colquhoun; Kudakwashe Chani; Tauhid Islam; Kalpeshsinh Rahevar; Fukushi Morishita; Anthony Byrne; Justin Clark; Kerri Viney
Journal:  BMC Med       Date:  2021-09-09       Impact factor: 8.775

3.  Treatment outcome among Post TB obstructive airways diseases and COPD: A prospective cohort study.

Authors:  Smrutirekha Swain; Sudarsan Pothal; Aurobindo Behera; Rekha Manjhi; Pravati Dutta; Gourahari Pradhan
Journal:  J Family Med Prim Care       Date:  2021-09-30

4.  Pulmonary Functions and Inflammatory Biomarkers in Post-Pulmonary Tuberculosis Sequelae.

Authors:  Kumar Shanmugasundaram; Anjana Talwar; Karan Madan; Geetanjali Bade
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.